CN105999238A - 用于治疗酸性鞘磷脂酶缺乏的剂量递增酶替代疗法 - Google Patents

用于治疗酸性鞘磷脂酶缺乏的剂量递增酶替代疗法 Download PDF

Info

Publication number
CN105999238A
CN105999238A CN201610404696.3A CN201610404696A CN105999238A CN 105999238 A CN105999238 A CN 105999238A CN 201610404696 A CN201610404696 A CN 201610404696A CN 105999238 A CN105999238 A CN 105999238A
Authority
CN
China
Prior art keywords
hours
asm
dose
asmd
rhasm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610404696.3A
Other languages
English (en)
Chinese (zh)
Inventor
爱德华·H·舒克曼
罗伯特·J·德斯尼克
杰拉尔德·F·考克斯
劳拉·P·安德鲁斯
詹姆斯·M·默里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Icahn School of Medicine at Mount Sinai
Original Assignee
Genzyme Corp
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105999238(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp, Mount Sinai School of Medicine filed Critical Genzyme Corp
Publication of CN105999238A publication Critical patent/CN105999238A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Dermatology (AREA)
CN201610404696.3A 2009-08-28 2010-08-28 用于治疗酸性鞘磷脂酶缺乏的剂量递增酶替代疗法 Pending CN105999238A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23811309P 2009-08-28 2009-08-28
US61/238,113 2009-08-28
CN2010800439108A CN102596232A (zh) 2009-08-28 2010-08-28 用于治疗酸性鞘磷脂酶缺乏的剂量递增酶替代疗法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2010800439108A Division CN102596232A (zh) 2009-08-28 2010-08-28 用于治疗酸性鞘磷脂酶缺乏的剂量递增酶替代疗法

Publications (1)

Publication Number Publication Date
CN105999238A true CN105999238A (zh) 2016-10-12

Family

ID=43625265

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201610404696.3A Pending CN105999238A (zh) 2009-08-28 2010-08-28 用于治疗酸性鞘磷脂酶缺乏的剂量递增酶替代疗法
CN201610403228.4A Pending CN106047835A (zh) 2009-08-28 2010-08-28 用于治疗酸性鞘磷脂酶缺乏的剂量递增酶替代疗法
CN2010800439108A Pending CN102596232A (zh) 2009-08-28 2010-08-28 用于治疗酸性鞘磷脂酶缺乏的剂量递增酶替代疗法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201610403228.4A Pending CN106047835A (zh) 2009-08-28 2010-08-28 用于治疗酸性鞘磷脂酶缺乏的剂量递增酶替代疗法
CN2010800439108A Pending CN102596232A (zh) 2009-08-28 2010-08-28 用于治疗酸性鞘磷脂酶缺乏的剂量递增酶替代疗法

Country Status (30)

Country Link
US (9) US8349319B2 (cg-RX-API-DMAC7.html)
EP (4) EP2470199B1 (cg-RX-API-DMAC7.html)
JP (8) JP5955219B2 (cg-RX-API-DMAC7.html)
KR (6) KR102094253B1 (cg-RX-API-DMAC7.html)
CN (3) CN105999238A (cg-RX-API-DMAC7.html)
AU (6) AU2010286550B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012004377A2 (cg-RX-API-DMAC7.html)
CA (1) CA2773133A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012000495A1 (cg-RX-API-DMAC7.html)
CY (1) CY1122128T1 (cg-RX-API-DMAC7.html)
DK (3) DK3482767T3 (cg-RX-API-DMAC7.html)
ES (3) ES3052684T3 (cg-RX-API-DMAC7.html)
FI (2) FI3998078T3 (cg-RX-API-DMAC7.html)
FR (1) FR22C1062I2 (cg-RX-API-DMAC7.html)
HR (3) HRP20251310T1 (cg-RX-API-DMAC7.html)
HU (3) HUE057440T2 (cg-RX-API-DMAC7.html)
IL (4) IL314807A (cg-RX-API-DMAC7.html)
LT (4) LT3998078T (cg-RX-API-DMAC7.html)
LU (1) LUC00288I2 (cg-RX-API-DMAC7.html)
MX (2) MX356873B (cg-RX-API-DMAC7.html)
NL (1) NL301211I2 (cg-RX-API-DMAC7.html)
NO (1) NO2022054I1 (cg-RX-API-DMAC7.html)
PL (3) PL2470199T3 (cg-RX-API-DMAC7.html)
PT (3) PT3482767T (cg-RX-API-DMAC7.html)
RU (2) RU2731616C2 (cg-RX-API-DMAC7.html)
SI (3) SI2470199T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500432T1 (cg-RX-API-DMAC7.html)
TR (1) TR201911293T4 (cg-RX-API-DMAC7.html)
WO (1) WO2011025996A2 (cg-RX-API-DMAC7.html)
ZA (2) ZA201201435B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111344003A (zh) * 2017-08-24 2020-06-26 赛诺菲 酸性鞘磷脂酶缺乏症患者中异常骨病症的治疗

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
US20080228056A1 (en) 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
PL2158322T3 (pl) 2007-06-06 2017-10-31 Genzyme Corp Terapia genowa dla lizosomalnych chorób spichrzeniowych
CA2773133A1 (en) * 2009-08-28 2011-03-03 Edward H. Schuchman Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
US8882701B2 (en) 2009-12-04 2014-11-11 Smiths Medical Asd, Inc. Advanced step therapy delivery for an ambulatory infusion pump and system
EP2571997A2 (en) 2010-05-21 2013-03-27 Ohmx Corporation Enzymatic activity of psa as diagnostic marker for prostate cancer
LT2685986T (lt) 2011-03-18 2020-03-10 Genzyme Corporation Gliukozilceramido sintazės slopiklis
US10350277B2 (en) 2011-09-07 2019-07-16 Icahn School Of Medicine At Mount Sinai Ceramidase and cell differentiation
JP6243846B2 (ja) 2011-11-15 2017-12-06 セントジーン アーゲー ニーマン・ピック病の診断のための方法
ES2786128T3 (es) 2012-06-01 2020-10-08 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
JP6832158B2 (ja) 2013-03-14 2021-02-24 アイカーン スクール オブ メディシン アット マウント サイナイ 治療用酸性セラミダーゼ組成物ならびにそれを作製および使用する方法
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
TR201906195T4 (tr) * 2013-05-14 2019-05-21 Centogene Ag Niemann pıck hastalığının teşhisi için metot.
MX370570B (es) 2013-06-07 2019-12-17 Genzyme Corp Marcador para trastornos de la esfingomielinasa acida y sus usos.
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病c型を予防または治療するための医薬組成物
US10569016B2 (en) 2015-12-29 2020-02-25 Tandem Diabetes Care, Inc. System and method for switching between closed loop and open loop control of an ambulatory infusion pump
FR3070383B1 (fr) 2017-08-31 2021-08-20 Solable Appareil de traitement d'eau
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
PY1939780A (es) * 2018-05-25 2019-12-04 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
PT3920912T (pt) 2019-02-04 2025-09-09 Genzyme Corp Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
IL295255A (en) 2020-02-03 2022-10-01 Genzyme Corp Methods for treating neurological symptoms associated with lysosomal storage diseases
IL300090A (en) 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT
CN117396517A (zh) * 2021-05-27 2024-01-12 梨树爱博思股份有限公司 与酸性鞘磷脂酶蛋白特异性结合的抗体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048047A1 (en) * 2003-08-29 2005-03-03 Kakkis Emil D. Delivery of therapeutic compounds to the brain and other tissues
CN1608138A (zh) * 2001-12-21 2005-04-20 艾蒂尔药物有限公司 检测碱性鞘磷脂酶的分析方法以及用于该方法的试剂盒
US20070280925A1 (en) * 2000-06-19 2007-12-06 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
IL74761A0 (en) 1984-04-13 1985-06-30 Hughes Howard Med Inst Human phenylalanine hydroxylase cdna clones,their production and their use in diagnosing classical phenylketonuria
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4863195A (en) * 1987-10-02 1989-09-05 Capozzola Carl A Identification tag
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
EP0865499B1 (en) 1995-09-14 2009-03-18 Virginia Tech Intellectual Properties, Inc. Production of lysosomal enzymes in plant-based expression systems
JP2820106B2 (ja) 1996-02-29 1998-11-05 日本電気株式会社 トラヒックシェーパ装置
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
MXPA01006491A (es) 1998-12-23 2003-06-06 Thompson Boyce Plant Res Expresion de antigenos de superficie de hepatitis b inmunogenicos en plantas transgenicas.
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6770799B2 (en) 2000-03-17 2004-08-03 Thompson Boyce Plant Res Expression of recombinant human acetylcholinesterase in transgenic plants
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
AU2001286636A1 (en) 2000-08-25 2002-03-13 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
EP1436316B1 (en) 2001-04-30 2008-01-23 ZyStor Therapeutics , Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
US7585518B2 (en) 2002-11-19 2009-09-08 Kimberly-Clark Worldwide, Inc. Products and methods for maintaining or increasing ceramide levels in skin
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
BRPI0411291A (pt) * 2003-06-12 2006-08-01 Genzyme Corp esfingomielinase acida humana modificada tendo atividade aumentada e métodos para a fabricação da mesma
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
CN1897957A (zh) 2003-11-25 2007-01-17 纽约大学西奈山医学院 尼曼-皮克病的基于陪伴分子的治疗
KR20070085291A (ko) 2004-10-13 2007-08-27 프로탈릭스 리미티드 식물 세포 배양에서 항체를 생산하는 시스템 및 방법
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
CA2634042A1 (en) 2005-12-15 2007-07-12 The Research Foundation Of State University Of New York Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
CA2641070C (en) 2006-02-06 2017-01-03 Ramot At Tel-Aviv University Ltd. Enzyme replacement therapy for treating lysosomal storage diseases
CN101404927A (zh) * 2006-02-09 2009-04-08 建新公司 慢速脑室内递送
US8124103B2 (en) 2006-02-13 2012-02-28 Fraunhofer Usa, Inc Influenza antigens, vaccine compositions, and related methods
JP5302189B2 (ja) 2007-04-27 2013-10-02 長瀬産業株式会社 スフィンゴミエリナーゼ
US20110237538A1 (en) 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
EP3608330B1 (en) 2008-12-16 2022-11-09 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates
CA2773133A1 (en) * 2009-08-28 2011-03-03 Edward H. Schuchman Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
ES2664844T3 (es) * 2011-06-20 2018-04-23 Mount Sinai School Of Medicine Tratamiento dirigido contra TNF para las mucopolisacaridosis y otros trastornos lisosómicos
MX370570B (es) * 2013-06-07 2019-12-17 Genzyme Corp Marcador para trastornos de la esfingomielinasa acida y sus usos.
PL3672622T3 (pl) * 2017-08-24 2024-04-02 Genzyme Corporation Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070280925A1 (en) * 2000-06-19 2007-12-06 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
CN1608138A (zh) * 2001-12-21 2005-04-20 艾蒂尔药物有限公司 检测碱性鞘磷脂酶的分析方法以及用于该方法的试剂盒
US20050048047A1 (en) * 2003-08-29 2005-03-03 Kakkis Emil D. Delivery of therapeutic compounds to the brain and other tissues

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111344003A (zh) * 2017-08-24 2020-06-26 赛诺菲 酸性鞘磷脂酶缺乏症患者中异常骨病症的治疗
CN111344003B (zh) * 2017-08-24 2024-05-07 建新公司 酸性鞘磷脂酶缺乏症患者中异常骨病症的治疗

Also Published As

Publication number Publication date
CN106047835A (zh) 2016-10-26
NL301211I2 (nl) 2023-02-02
KR20210107153A (ko) 2021-08-31
US20180055916A1 (en) 2018-03-01
ES3052684T3 (en) 2026-01-13
JP7605949B2 (ja) 2024-12-24
PL2470199T3 (pl) 2019-11-29
HUS2200050I1 (hu) 2022-12-28
ZA201201435B (en) 2020-05-27
SI2470199T1 (sl) 2019-11-29
CA2773133A1 (en) 2011-03-03
RU2020128994A (ru) 2022-03-02
TR201911293T4 (tr) 2019-08-21
SI3998078T1 (sl) 2026-02-27
EP4681775A2 (en) 2026-01-21
US20110052559A1 (en) 2011-03-03
IL266915B1 (en) 2023-03-01
RU2569744C2 (ru) 2015-11-27
AU2016216625B2 (en) 2018-07-05
LT2470199T (lt) 2019-10-10
JP7395693B2 (ja) 2023-12-11
US20130078231A1 (en) 2013-03-28
CN102596232A (zh) 2012-07-18
ES2902229T3 (es) 2022-03-25
LUC00288I2 (cg-RX-API-DMAC7.html) 2025-05-12
DK3998078T3 (da) 2025-11-17
IL300625B2 (en) 2025-01-01
IL300625B1 (en) 2024-09-01
JP7167281B2 (ja) 2022-11-08
AU2020256322A1 (en) 2020-11-12
US20190151419A1 (en) 2019-05-23
JP6952810B2 (ja) 2021-10-20
AU2025205539A1 (en) 2025-08-07
AU2020256322B2 (en) 2024-02-29
RU2731616C2 (ru) 2020-09-07
LTC3482767I2 (cg-RX-API-DMAC7.html) 2024-03-25
PL3998078T3 (pl) 2026-02-16
JP2024026214A (ja) 2024-02-28
DK3482767T3 (da) 2021-12-20
FI3998078T3 (fi) 2025-12-04
US8658162B2 (en) 2014-02-25
CL2012000495A1 (es) 2014-02-07
KR102893390B1 (ko) 2025-11-28
US8349319B2 (en) 2013-01-08
EP3482767B1 (en) 2021-10-06
IL218324A0 (en) 2012-04-30
BR112012004377A2 (pt) 2017-12-12
SMT202500432T1 (it) 2026-01-12
JP2020090513A (ja) 2020-06-11
HUE046598T2 (hu) 2020-03-30
FR22C1062I1 (fr) 2023-02-03
PT3482767T (pt) 2021-12-29
KR20220104271A (ko) 2022-07-26
JP5955219B2 (ja) 2016-07-20
RU2015145255A (ru) 2019-01-11
AU2010286550A1 (en) 2012-03-15
HRP20211992T1 (hr) 2022-04-01
WO2011025996A3 (en) 2012-03-15
AU2024201085B2 (en) 2025-04-24
NO2022054I1 (no) 2022-12-01
KR20250171458A (ko) 2025-12-08
JP2013502933A (ja) 2013-01-31
US10188705B2 (en) 2019-01-29
AU2018204156B2 (en) 2020-07-16
EP3482767A1 (en) 2019-05-15
FIC20220051I1 (fi) 2022-12-20
KR102608551B1 (ko) 2023-12-04
ZA201601362B (en) 2017-05-31
RU2012111823A (ru) 2013-10-10
PT2470199T (pt) 2019-08-07
AU2010286550B2 (en) 2016-05-19
MX356873B (es) 2018-06-18
NL301211I1 (nl) 2022-12-28
KR102094253B1 (ko) 2020-03-31
EP2470199B1 (en) 2019-05-22
KR20200034828A (ko) 2020-03-31
HRP20251310T1 (hr) 2026-01-02
CY1122128T1 (el) 2020-11-25
US9114139B2 (en) 2015-08-25
SI3482767T1 (sl) 2022-03-31
AU2018204156A1 (en) 2018-06-28
ES2738859T3 (es) 2020-01-27
AU2024201085A1 (en) 2024-03-07
IL266915B2 (en) 2023-07-01
JP6251307B2 (ja) 2017-12-20
HUE057440T2 (hu) 2022-05-28
IL300625A (en) 2023-04-01
WO2011025996A2 (en) 2011-03-03
HRP20191385T1 (hr) 2019-11-01
PL3482767T3 (pl) 2022-02-14
RU2015145255A3 (cg-RX-API-DMAC7.html) 2019-08-12
US20210077593A1 (en) 2021-03-18
AU2016216625A1 (en) 2016-09-15
MX392330B (es) 2025-03-11
IL266915A (en) 2019-07-31
US20220305091A1 (en) 2022-09-29
EP3998078B1 (en) 2025-10-01
EP3998078A1 (en) 2022-05-18
EP2470199A4 (en) 2013-03-27
KR20120081077A (ko) 2012-07-18
US20140335070A1 (en) 2014-11-13
LT3482767T (lt) 2022-01-10
PT3998078T (pt) 2025-11-07
IL218324B (en) 2019-05-30
US20160120957A1 (en) 2016-05-05
MX2012002449A (es) 2012-03-14
JP2022003065A (ja) 2022-01-11
WO2011025996A9 (en) 2011-08-25
FR22C1062I2 (fr) 2023-12-29
EP2470199A2 (en) 2012-07-04
EP4681775A3 (en) 2026-04-01
US9655954B2 (en) 2017-05-23
US8709408B2 (en) 2014-04-29
IL314807A (en) 2024-10-01
JP2018076322A (ja) 2018-05-17
US20130078230A1 (en) 2013-03-28
JP2016153408A (ja) 2016-08-25
KR102608546B1 (ko) 2023-12-04
LT3998078T (lt) 2025-12-29
DK2470199T3 (da) 2019-08-05
JP2025038063A (ja) 2025-03-18
JP2023012499A (ja) 2023-01-25
KR20230164773A (ko) 2023-12-04

Similar Documents

Publication Publication Date Title
JP7605949B2 (ja) 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
RU2833674C2 (ru) Ферментная заместительная терапия с увеличением дозы для лечения недостаточности кислой сфингомиелиназы

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: American New York

Applicant after: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

Applicant after: GENZYME Corp.

Address before: American New York

Applicant before: MOUNT SINAI SCHOOL OF MEDICINE

Applicant before: Genzyme Corp.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20161012